Search Results
Your search for ,ARE matches 21421 pages
Showing 5551 - 5600EA1131 Trial: Platinum Not Equal to Capecitabine for Residual Disease in Triple-Negative Breast Cancer
In patients with triple-negative breast cancer who have residual disease after neoadjuvant chemotherapy, adjuvant capecitabine remains the standard of care. In the multicenter randomized noninferiority EA1131 trial, which included primarily basal tumors, noninferiority of adjuvant platinum over...
Amivantamab/Lazertinib Combination May Overcome Osimertinib Resistance in Patients With EGFR-Positive NSCLC
Combination targeting of epidermal growth factor receptor (EGFR) with amivantamab/lazertinib achieved durable responses in more than one-third of chemotherapy-naive patients with EGFR-mutant non–small cell lung cancer (NSCLC) that had progressed on osimertinib, according to a cohort analysis of the ...
Novel Targeted Agents for the Treatment of Myelofibrosis
“Progress lies not in enhancing what is, but in advancing toward what will be.” –Kahlil Gibran To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting &...
Novel BCL2 Inhibitor Shows Activity in CLL in Phase I Trial
The novel, selective BCL2 inhibitor lisaftoclax (APG-2575) has shown activity in the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) in a phase I study reported at the 2021 ASCO Annual Meeting.1 Preliminary data suggest that lisaftoclax stands out for its favorable safety...
Early Adopter of Breast Conservation, Surgical Oncologist Augusto Leon, MD, Reflects on Cancer Care in Chile
In this installment of the occasional department on Global Health-Care Equity, Guest Editor, Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Augusto Leon, MD, a surgical oncologist and Head of the Program of Cancer at Pontifical University of Chile, Santiago. Dr. Are is JL & CJ Varner...
Lifileucel After Disease Progression in Metastatic Melanoma: Durable Responses Achieved in Phase II Trial
Despite the fact that we have made significant progress in metastatic melanoma with immune checkpoint inhibitors—now the standard of care—most patients experience disease progression and are left without approved treatments. There is a need for newer treatments with clinical benefit. Lifileucel, an ...
Predicting Global Cancer Trends in 2021
Although we are just halfway through 2021, the outlook for improvements in global cancer trends looks grim. According to new estimates by the International Agency for Research on Cancer’s Global Cancer Observatory, the global cancer burden rose to 19.3 million cases and 10 million deaths in 2020...
ADAPT Trial: ‘Excellent’ Outcomes Reported With Neoadjuvant Dual HER2 Therapy in Breast Cancer
The first overall survival analysis of the WGS-ADAPT HER2+/HR– study, which evaluated neoadjuvant therapy in patients with hormone receptor–negative, HER2-positive disease, showed that treatment with pertuzumab and trastuzumab plus paclitaxel—or with the chemotherapy-free regimen of...
Sacituzumab Govitecan-hziy: Welcome Addition to Advanced Urothelial Cancer Treatments, but Time to Figure Out Sequencing and Combinations
The results of Cohort 1 of the phase II trial TROPHY-U-01 (IMMU-132-06; ClinicalTrials.gov identifier NCT03547973), published in the Journal of Clinical Oncology by Tagawa et al and reviewed in this issue of The ASCO Post, led to the recent accelerated U.S. Food and Drug Administration (FDA)...
Reducing Prostate Cancer Disparity by Bringing Care to Underserved Populations
The dire cancer incidence and mortality statistics for Black patients compared with White patients are well known. Collectively, Black individuals have the highest mortality rate and shortest survival of any racial or ethnic group in the United States for most cancers. Black men also have the...
Enfortumab Vedotin Represents a Community of Work in Antibody-Drug Conjugates Targeting Cancer
The first known clinical trial report of an antibody-drug conjugate was a phase 0/I pharmacodynamic and safety study of a conjugate that targeted carcinoembryonic antigen and delivered a payload of vinca alkaloid in eight patients with ovarian or colorectal cancer.1 This work built on the work of...
Disease Risk Associated With Protein-Truncating and Rare Missense Variants in Breast Cancer Risk Genes
In a study reported in TheNew England Journal of Medicine, Leila Dorling, PhD, of the Centre for Cancer Genetic Epidemiology, Departments of Public Health and Primary Care, University of Cambridge, United Kingdom, and colleagues in the international Breast Cancer Association Consortium (BCAC),...
The Wistar Institute Recruits Noam Auslander, PhD, as Assistant Professor
The Wistar Institute, an international biomedical research leader in cancer, immunology, and infectious diseases, recently announced the appointment of Noam Auslander, PhD, as Assistant Professor in the Molecular and Cellular Oncogenesis Program of The Wistar Institute Cancer Center. Dr....
Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
On May 20, 2021, nivolumab was approved for adjuvant treatment of patients with completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease after neoadjuvant chemoradiotherapy.1,2 Supporting Efficacy Data Approval was based on findings from the...
Enfortumab Vedotin-ejfv Granted Regular Approval in Treatment of Locally Advanced or Metastatic Urothelial Cancer
On July 9, 2021, the U.S. Food and Drug Administration (FDA) approved enfortumab vedotin-ejfv (Padcev), a Nectin-4–directed antibody and microtubule inhibitor conjugate, for adults with locally advanced or metastatic urothelial cancer who have previously received a PD-1 or PD-L1 inhibitor and...
Study Finds Response to COVID-19 Vaccination Varies Widely in Patients With Multiple Myeloma
Patients with multiple myeloma had a wide variety of responses to COVID-19 vaccines—in some cases, no detectable response at all—pointing to the need for antibody testing and precautions for these patients after vaccination, according to a study published by Van Oekelen et al in Cancer Cell. Mount...
Is There a Link Between Use of Antibiotics and Early-Onset Colorectal Cancer?
Study findings presented by Perrott et al at the ESMO World Congress on Gastrointestinal Cancer (Abstract SO-25) showed that the use of antibiotics may be linked to colon tumor formation across all patient age groups, especially in those younger than 50 years. These results raise fresh concerns...
Annual Report to the Nation: Continued Decline in Cancer Death Rate
Overall cancer death rates continue to decline in men and women for all racial and ethnic groups in the United States, according to the latest Annual Report to the Nation on the Status of Cancer. During 2001 to 2018, declines in lung cancer death rates accelerated, and death rates for melanoma...
Parenthood Status and Use of Assisted Reproductive Techniques in Younger Hodgkin Lymphoma Survivors
In a Danish population-based study reported in the Journal of Clinical Oncology, Øvlisen et al found that parenthood rates in younger Hodgkin lymphoma survivors who did not experience early relapse were similar to those in the general population, but that use of assisted reproductive techniques...
Study Recommends Improvements for Cancer Care at Network Sites
New research published in JNCCN—Journal of the National Comprehensive Cancer Network assessed the quality of cancer care delivered through extended sites coordinated by some of the country’s largest cancer centers. The study was developed to implement strategies for disseminating discoveries and...
Mechanisms of Acquired Resistance to KRAS G12C Inhibition in Patients With Cancer
In a study reported in The New England Journal of Medicine, Awad et al identified potential mechanisms of acquired resistance to the KRAS G12C inhibitor adagrasib in patients receiving the agent for treatment of KRAS G12C–mutant cancers. As noted by the investigators, clinical trials of the KRAS...
New Recommendations From WHO and HRP for the Screening and Treatment of Cervical Cancer
The World Health Organization (WHO) and the Human Reproduction Programme (HRP)—the main instrument within the United Nations system for research in human reproduction—have launched a new guideline to help countries make faster progress, more equitably, in the screening and treatment of cervical...
Study Finds Reduced Treatment Delays for Patients With Breast Cancer May Improve Survival Rates
Research published by Pratt et al in Annals of Surgical Oncology showed an increase in survival rates when treatment options—surgery, chemotherapy, and radiation—are completed within 38 weeks from the time of diagnosis for patients with breast cancer. Optimal Treatment Duration The observational...
Individualized Nutritional Support for Patients With Cancer
Among 506 hospitalized patients with cancer at risk of malnutrition, individualized nutritional support reduced the risk of mortality compared to consumption of standard hospital food. The findings from a preplanned secondary analysis of the prospective, randomized, multicenter EFFORT trial,...
International Esodata Study Group Model for Predicting 90-Day Mortality After Esophagectomy
In a retrospective analysis reported by researchers from the International Esodata Study Group (IESG) in JAMA Surgery, D’Journo et al developed a model for predicting risk of 90-day mortality following esophagectomy for patients with esophageal or gastroesophageal junction cancer. As stated by the...
Study Explores Co-occurring Mutations in HER2 and HER3
Mutations in a gene related to HER2, a gene frequently implicated in breast cancers and a variety of other malignancies, can amplify activity that spurs tumor growth, according to a new study. The findings, published by Hanker et al in Cancer Cell, could explain why many patients with HER2...
A Shift in the Treatment of Advanced Melanoma
Answers to questions about first-line treatment of metastatic melanoma are “going to be shifting,” Jason J. Luke, MD, told The ASCO Post, with the change coming on the heels of the phase III RELATIVITY-047 trial reported at the 2021 ASCO Annual Meeting.1 That abstract reported that using two...
Responses to Pembrolizumab and Ipilimumab After Anti–PD-1/L1 Failure in Advanced Melanoma
Despite new and effective treatments for melanoma with checkpoint inhibitors and targeted therapies, patients with metastatic melanoma who progress on frontline treatment generally do very poorly. “We really need to make sure we give these patients access to drugs that we know have some efficacy,”...
Effect of ALK Amplification and Mutation on Outcomes in High-Risk Neuroblastoma
In an analysis from the European Neuroblastoma Study Group (SIOPEN) HR-NBL1 high-risk neuroblastoma trial reported in the Journal of Clinical Oncology, Bellini et al found that ALK amplification and clonal mutation were associated with poorer outcomes in pediatric patients with high-risk...
FDA Pipeline: Recent Designations in NSCLC, Leukemia, and Lymphoma
Recently, the U.S. Food and Drug Administration (FDA) issued regulatory decisions related to treatments for non–small cell lung cancer (NSCLC), acute leukemia, and mantle cell lymphoma. Breakthrough Therapy Designation for Adagrasib in Advanced NSCLC With KRAS G12C Mutation On June 24, 2021, the...
Expert Point of View: Rebecca A. Snyder, MD, MPH
The invited discussant of the Alliance A21501 findings, Rebecca A. Snyder, MD, MPH, Assistant Professor of Surgical Oncology at the Brody School of Medicine at East Carolina University, Greenville, described the overall survival associated with modified FOLFIRINOX (fluorouracil [5-FU], leucovorin, ...
Modified FOLFIRINOX Established as Preferred Neoadjuvant Treatment of Borderline Resectable Pancreatic Cancer
In the treatment of borderline resectable pancreatic ductal adenocarcinoma, the Alliance A021501 trial established neoadjuvant treatment with modified FOLFIRINOX (fluorouracil [5-FU], leucovorin, irinotecan, oxaliplatin) as a new benchmark. However, it failed to show the benefit of adding...
Personalizing Treatment of Early HER2-Positive Breast Cancer
With several pivotal trials providing evidence for the escalation and de-escalation of anti-HER2 therapy in certain early breast cancer scenarios, personalized treatment is possible. How can clinicians optimize treatment by applying the studies’ findings? Debu Tripathy, MD, Professor and Chair of...
Association Between Increased BMI and Endometrial Cancer Risk in Asian Women With Postmenopausal Bleeding
The link between obesity and the risk of endometrial cancer has been well documented. A recent study, however, showed that an even lower body mass index (BMI) than previously thought may be associated with an increased risk in Asian women with postmenopausal bleeding. The findings by Liu et al were ...
Study Examines Mechanisms of Resistance in Early-Stage Breast Cancer After Endocrine Plus CDK4/6 Therapy
About 80% of breast cancer cases are hormone receptor–positive, according to the American Cancer Society. Patients with estrogen receptor–positive breast cancer generally are treated using therapy that inhibits both estrogen levels and cell-cycle activity, but about 90% of patients with metastatic...
Immunotherapy May Be Effective for Subset of Patients With Prostate Cancer
In recent years, cancer immunotherapy has been effective in treating patients with immunogenic—or “hot”—tumors with increased levels of inflammation and the presence of immune cells in and around the tumors. Prostate cancer, however, is considered a “cold” tumor, with few immune cells recognizing...
Beyond CDK4/6 Inhibitors in Metastatic Breast Cancer: What’s Next?
Because of their well-established efficacy, inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) are the standard of care in the treatment of hormone receptor–positive, HER2-negative metastatic breast cancer. The question now is this: after disease progresses on a CDK4/6 inhibitor and endocrine...
Are Patients With Primary Lung Cancer Detected by Low-Dose CT at Reduced Risk of Brain Metastases?
Patients with primary lung cancer detected using low-dose computed tomography (CT) screening may be at reduced risk for developing brain metastases after diagnosis, according to a study published in the Journal of Thoracic Oncology. The researchers, led by Summer Han, PhD, of Stanford University...
Improving Screening of Dense Breasts With Newer MRI Technologies
Women with dense breasts are increasingly being screened with magnetic resonance imaging (MRI), which is clearly the best way to detect small cancers in this population, according to Elizabeth Morris, MD, FACR, FSBI, FISMRM, Professor and Chair of the Department of Radiology at the University of...
Effects of FOXR2 Expression in Neuroblastoma
In a study reported in the Journal of Clinical Oncology, Schmitt-Hoffner et al found that FOXR2 expression is associated with poorer survival in neuroblastoma, identifying a subgroup of patients in addition to those with MYCN-amplified tumors who are at risk of unfavorable outcomes. They found that ...
ASCO-ACCC Piloting Project to Test Tools to Diversify Cancer Clinical Trials
In a continuation of their collaboration to increase clinical trial participation among patients from underrepresented racial and ethnic groups, ASCO and the Association of Community Cancer Centers (ACCC) recently announced plans to test a research site assessment tool and implicit bias training...
Watch Now: Discussion on Eligibility Criteria and the Impact on Access to Clinical Trials
On Friday, April 9, 2021, ASCO and Friends of Cancer Research (Friends) co-hosted a live virtual event, which brought together experts from across the health-care sector to discuss the recent release of the new ASCO-Friends recommendations for modernizing eligibility criteria to improve patient...
ASCO Releases Recommendations for Management of Salivary Gland Malignancies
Given the rarity of salivary gland malignancies—neoplasms that account for less than 1% to 5% of all head and neck cancers—limited evidence exists to support informed treatment guidance. The overall variability in the biologic behaviors of these neoplasms has further complicated clinical...
New ASCO Journal Series Examines Disparities in Cancer Care for Black People in the United States
A new special series in JCO Oncology Practice explores the causes of disparities in cancer care and outcomes for Black people in the United States and examines potential solutions to begin to achieve health equity for this population. The “Disparities in Cancer Care for Black People in the United...
Emerging Reasons for Optimism in Lung Cancer
Despite public smoking cessation initiatives and improved methods for early detection and treatment, lung cancer persists as the leading cause of cancer death in both men and women in the United States. However, over the past decade, smoking cessation efforts, increased screening, and new...
How to Talk With Teens and Young Adults About Their End-of-Life Goals
Although death rates for adolescent and young adults (AYAs) with cancer have been dropping 0.8% a year from 2009 to 2018, cancer remains a leading disease-related cause of death among this patient population. This year, the National Cancer Institute (NCI) estimates that 88,260 AYAs, defined by the...
Better Responses to Hepatic Arterial Infusion Therapy Among Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Patients with colorectal cancer and unresectable liver metastases and KRAS wild-type disease experienced better responses to hepatic arterial infusion pump chemotherapy than did patients with KRAS mutations, a retrospective cohort study found. At a median follow-up of 14.6 months, “KRAS-positive...
Survey Finds Bullying, Sexual Harassment Not Uncommon for Women in Gynecologic Oncology
Female gynecologic oncologists have reported in a survey that having a department chair of the same gender is no buffer against gender harassment or discrimination in the workplace. The information comes from a survey of the “Women of Gynecologic Oncology” Facebook group and was reported in March...
NIH Names Marie A. Bernard, MD, Chief Officer for Scientific Workforce Diversity
National Institutes of Health (NIH) Director Francis S. Collins, MD, PhD, has selected Marie A. Bernard, MD, as NIH’s next Chief Officer for Scientific Workforce Diversity (COSWD). Dr. Bernard will lead NIH’s effort to promote diversity, inclusiveness, and equity throughout the biomedical research...
Expert Point of View: Rui-Hua Xu, MD, PhD
David Cunningham, MD, Consultant Medical Oncologist, Head of the Gastrointestinal and Lymphoma Unit, and Director of Clinical Research at The Royal Marsden in London and Surrey in the United Kingdom, discussed CheckMate 6481 as well as the ESCORT-1st study of the PD-L1 inhibitor camrelizumab in...
